BY MARIA OUTZE NIELSEN
-
Lundbeck boss is open to use of external distributors in selected markets
As component of a reallocation of sources to enhance the R&D division specifically, Lundbeck is seeking outside suppliers in chosen markets to change its very own sales compan…
-
Trade group: Trump’s tariff threats could affect US drug supply
Donald Trump’s punishing tolls will eventually influence individuals’ accessibility to life-saving medications, advises United States profession team.
-
Lundbeck CEO is “very satisfied” despite lower-than-expected sales of key products
Lundbeck provided lower-than-expected sales of essential items Vyepti and Rexulti in the 4th quarter, yet chief executive officer Charl van Zyl prefer to concentrate on the develop…
-
Lundbeck to apply for Asian approval of blockbuster migraine drug in 2025
Lundbeck’s migraine drug Vyepti has the potential for vital development if given the inexperienced gentle in Asia, says the corporate’s US CEO.
-
Bavarian Nordic enters lucrative market with approval for “important” vaccine
New EMA recommendation could mean a European launch of Bavarian Nordic’s chikungunya vaccine within six months. Meanwhile, another important decision lies ahead.
-
Weight-loss drug developer targets USD 1.78bn valuation on Nasdaq
US-based Metsera is amongst the lots of business concentrating on creating medications for the international excessive weight market.
-
EMA joins mass exodus from Elon Musk’s social media
Elon Musk’s social networks X no more matches the European Medicines Company’s interaction requirements, the EMA reveals.
-
Weight-loss drug developer targets USD 1.78bn valuation on Nasdaq
US-based Metsera is among the many companies focusing on developing drugs for the global obesity market.
-
Ambu CEO keeps quiet about countermeasures to Trump’s tariff threat – but has several scenarios in play
Ambu has actually not begun relocating manufacturing in spite of the hazard of tolls versus Mexico, where the clinical business creates endoscopes for the United States market.
-
Orifarm announces layoffs
According to Orifarm’s interactions principal, the discharges will certainly not impact the Danish pharmaceutical business’s manufacturing.
